A Phase 3 interventional study of MenACYW conjugate vaccine and MenACYW135 polysaccharide vaccine in Meningococcal Infection and Healthy Volunteers, sponsored by Sanofi. Completed at 4 sites in China. Open to participants aged 2 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Meningococcal Infections by Sanofi — 2 open to participants now, 2 under way, 1 of them phase 3. Meningococcal Infections · Sanofi.
Among the 57 studies in Meningococcal Infections by Sanofi, this one is the 7th largest by enrollment of the 51 interventional ones that give a count, is the only one that started in 2025, is one of 25 in phase 3, and was the 56th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →2 of the 57 studies in Meningococcal Infections by Sanofi are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 2 mo–23 mo · Healthy volunteers
Sanofi Pasteur, a Sanofi Company · Sites in United States
Healthy volunteers
By country, each count listing its studies:
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 25 · Phase 4 8
First in 2002; this study’s year is marked. 1 started in 2025.
This study's enrollment of 1,602 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 378 across the 51 interventional studies, 440 across the 6 observational. Of the 55 that completed or were terminated, 51 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Meningococcal Infections by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, modified double-blind, randomized, parallel-group, active-controlled, multicenter study with 2 arms and 4 groups to evaluate the immunogenicity and safety of MenACYW conjugate vaccine in children and adolescents versus control meningococcal vaccines licensed in China.
Study details include:
The duration of each participant's participation will be approximately 180 days.
Inclusion Criteria:
Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 dose of MenACYW conjugate vaccine to participants aged 7 through 17 years of age
Biological: MenACYW conjugate vaccine
1 dose of MenACYW135 polysaccharide vaccine to participants aged 7 through 17 years of age
Biological: MenACYW135 polysaccharide vaccine
1 dose of MenACYW conjugate vaccine to participants aged 2 through 6 years of age
Biological: MenACYW conjugate vaccine
1 dose of Royal's MenAC conjugate vaccine to participants aged 2 through 6 years of age
Biological: MenAC conjugate vaccine
Pharmaceutical form:Liquid solution-Route of administration:Intramuscular (IM) injection
Also known as: MenQuadfi
Pharmaceutical form: Lyophilized powder-Route of administration:IM injection
Pharmaceutical form:Lyophilized powder-Route of administration:IM injection
Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W
30 days postvaccination rSBA titer ≥1:8 for participants with prevaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days postvaccination for participants with pre vaccination rSBA titer ≥1:8
Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Participants 7 through 17 years of age (Cohort I): Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A, C, Y, and W
Antibodies titers are expressed as geometric mean titers
Time frame: Day 31 (post- vaccination)
Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups W and Y will be assessed in participants receiving MenACYW conjugate vaccine
30 days postvaccination rSBA titer ≥1:8 for participants with prevaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-vaccination for participants with pre vaccination rSBA titer ≥1:8
Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Participants 2 through 6 years of age (Cohort II): Vaccine seroresponse to meningococcal serogroups A and C
30 days postvaccination rSBA titer ≥1:8 for participants with prevaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days postvaccination for participants with pre vaccination rSBA titer ≥1:8
Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Participants 2 through 6 years of age (Cohort II): Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A and C
Antibody titers are expressed as geometric mean titers
Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Participants 2 through 6 years of age (Cohort II): Vaccine seroresponse to meningococcal serogroups W and Y in participants receiving MenACYW conjugate vaccine
30 days post-vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30◦days post-vaccination for participants with pre vaccination rSBA titer ≥1:8
Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W (Group 1)
30 days post vaccination rSBA titer ≥1:8 for participants with pre vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post vaccination for participants with pre vaccination rSBA titer ≥1:8
Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Number of participants with immediate adverse events (AEs)
Unsolicited systemic AEs that occur within 30 minutes after vaccination
Time frame: Within 30 minutes post-vaccination
Presence of solicited injection site reactions
Solicited injection site reactions include injection site pain, erythema and swelling
Time frame: Within 7 days post-vaccination
Presence of solicited systemic reactions
Solicited systemic reactions include fever, headache, malaise and myalgia
Time frame: Within 7 days post-vaccination
Presence of unsolicited AEs
Time frame: Within 30 days post-vaccination
Presence of SAEs
SAEs, including adverse events of special interest (AESIs), reported throughout the study
Time frame: Up to Day 181 post-vaccination
Participants 7 through 17 years of age (Cohort I): Antibody titers against meningococcal serogroups A, C, Y, and W in Groups 1 and 2
Antibody titers measured by rSBA titer ≥1:8, ≥1:128
Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Participants 2 through 6 years of age (Cohort II): Antibody titers against meningococcal serogroups A, C, Y, and W in Group 3 and against meningococcal serogroups A and C in Group 4
Antibody titers measured by rSBA titer ≥1:8, ≥1:128
Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Participants 2 through 6 years of age (Cohort II): Antibody titers in terms of GMTs against meningococcal serogroups Y and W in Group 3
Antibodies titers are expressed as geometric mean titers
Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2025 to primary completion in May 2026, 7 months.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 7 months is below that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.